The U.S. Food and Drug Administration has proposed that semaglutide, tirzepatide, and liraglutide—active ingredients in Novo Nordisk’s Wegovy, Ozempic, and Eli Lilly’s Zepbound and Mounjaro—be removed from the 503B outsourcing‑facility bulk compounding list. The proposal follows the FDA’s concern that compounding pharmacies could produce cheaper, unapproved versions of these drugs when FDA‑approved products are available, potentially undermining the companies’ pricing power and market share.
The proposal cites a lack of clinical need for outsourcing facilities to compound these drugs from bulk substances. By limiting the availability of mass‑compounded GLP‑1 agents, the FDA aims to reduce the risk of substandard products and protect the integrity of the approved drug supply chain. The move is expected to preserve Novo Nordisk’s and Eli Lilly’s revenue streams from their high‑margin obesity and diabetes therapies, which have driven significant growth in recent quarters.
Novo Nordisk’s Q1 2025 earnings showed revenue of $11.9 billion and operating profit of $5.9 billion, with diluted EPS up 15% year‑over‑year. The company’s gross profit margin has slipped from over 84% to 80% and operating margin from 36% to 33%, reflecting pricing pressure and increased investment in manufacturing capacity. The FDA proposal is viewed as a safeguard against the competitive threat posed by compounded alternatives, which could erode the company’s pricing power and margin trajectory.
Investors have welcomed the announcement, seeing it as a decisive regulatory win that protects the company’s blockbuster drug sales and supports its long‑term profitability. The proposal is expected to reinforce Novo Nordisk’s market position and may influence future pricing and margin expectations for the GLP‑1 segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.